Pure Global AI
NCT05705414Not yet recruiting

Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis

Oral Intradialytic Amino Acids Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis (OASIS)
The University of Texas Health Science Center at San AntonioPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
End Stage Renal Disease
Drug/Device/Intervention
Valine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
The University of Texas Health Science Center at San Antonio
Timeline & enrollment
Phase
Phase 1
Start date
Jul 01, 2023
End date
Aug 01, 2024
Enrollment
28 participants
Primary outcome

Brief Fatigue Inventory (BFI) score

Summary

The study will test and compare the efficacy of a single essential amino acid valine with a
 combination of essential amino acids (EAA) supplement on fatigue, frailty, and cognitive
 function in end-stage kidney disease (ESKD) patients undergoing hemodialysis (HD) treatment.

ICD-10 classifications
Chronic kidney disease, stage 1Chronic kidney disease, stage 5Chronic kidney disease, stage 2Chronic kidney disease, stage 3Chronic kidney disease, stage 4
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05705414
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05705414 through Pure Global AI's free database. This Phase 1 trial is sponsored by The University of Texas Health Science Center at San Antonio and is currently Not yet recruiting. The study focuses on End Stage Renal Disease. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.